WO2006038513A1 - 抗トリパノソーマ剤 - Google Patents
抗トリパノソーマ剤 Download PDFInfo
- Publication number
- WO2006038513A1 WO2006038513A1 PCT/JP2005/017927 JP2005017927W WO2006038513A1 WO 2006038513 A1 WO2006038513 A1 WO 2006038513A1 JP 2005017927 W JP2005017927 W JP 2005017927W WO 2006038513 A1 WO2006038513 A1 WO 2006038513A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- general formula
- atom
- ring
- ion
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention relates to a new use of oral dasyanin pigments, and in particular, to an antitrypanosomic agent useful for effective prevention and treatment of trypanosoma infections for which there is no currently effective treatment.
- Trypanosomiasis caused by Trypanosoma protozoa is roughly classified into two types depending on the genus species of causative parasites.
- the first is African 'trypanosomasis (african sleeping sickness) parasitized by Trypanosoma bruc.
- Gambia' trypanosoma ' ⁇ ma (Trypanosoma brucei gambiense) and mouth ⁇ Antolino ⁇ noso ⁇ ma
- Itoda is divided into Trypanosoma brucei rhodesiense.
- the second is Trypanosoma cruzi causative worm &) American trypanosomasis (Shiyagas disease).
- These protozoa infect not only humans but also various animals such as dogs, cats, horses and tusks, and trypanosomiasis is a concern worldwide.
- Africa 'In the trypanosomes human infections are estimated throughout the continent, with an estimated 60 million affected people ⁇ .
- Gambia's trypanosomes are found in West Africa and Central Africa, while Rhodesia's trypanosomes are found in East Africa and South Africa.
- Africa 'Trypanosomiasis is mediated by flies and can cause explosive spread in areas where public health is underdeveloped.
- the protozoa can be disseminated into the bloodstream or lymph nodes at the site of stinging the wings, resulting in intermittent fever, headache, chills, and transient edema. Later, when the central nervous system is attacked by protozoa, persistent headaches, daytime somnolence, ataxia, coma, and eventually death in several months and years.
- mouth Dashianin dye used in the present invention are known to be effective in the treatment of tumors (e.g., see JP Hei 5- 117148.) 0 Further, the present inventors have The rhodacyanine dye exhibits antimalarial activity (see, for example, Japanese Patent Application Laid-Open No. 2000-191531, Japanese Patent Application Laid-Open No. 2003-0334640, Japanese Patent Application Laid-Open No. 2003-033461, and Japanese Patent Application Laid-Open No. 2003-033461). is suggesting.
- Patent Document 1 Japanese Patent Laid-Open No. 5-117148
- Patent Document 2 Japanese Patent Laid-Open No. 2000-191531
- Patent Document 3 JP 2003-034640
- Patent Document 4 Japanese Patent Laid-Open No. 2003-034641
- Patent Document 5 Japanese Unexamined Patent Application Publication No. 2003-034642
- Non-patent literature l Hoet, S. et al., Natural Product Reports, 2004, 21 ⁇ , 353-36 4
- Non-Patent Document 2 Teixeira, M. M. et al., Trends Parasitology, 2002, 18 ⁇ , pp. 262-268
- An object of the present invention is to provide an anti-trypanosoma agent having high selective toxicity against trypanosomiasis including African trypanosomes and American trypanosomes, and having a high preventive or therapeutic effect. There is.
- the present inventors have synthesized a large number of compounds that can solve the above-mentioned problems, and as a result of conducting a number of pharmacological activity tests using the growth inhibitory effect of trypanoso monoprotozoa as an index, the results show that oral dasyanin dye is strong.
- the present inventors have found that it exhibits trypanosomal growth inhibitory activity and is extremely low toxic to mammalian cells that serve as an indicator of side effects, thereby completing the present invention.
- an antitrypanosomes agent comprising a compound represented by the following general formula (1) as an active ingredient
- R 1 and R 2 are each independently a hydrogen atom, a halogen atom, a hydroxyl group, an oxygen atom, or Child, C alkyl group, C alkoxy group, C aryl group, C aryloxy group, C
- R 6 and R 7 are each independently a hydrogen atom, a halogen atom, a hydroxyl group, an oxygen atom, a C1-8 alkyl group, a C1-5 alkoxy group, a C aryl group, a C aryloxy group.
- the present invention provides: [2]-The compound according to [1], wherein the compound represented by the general formula (1) is a compound represented by the following general formula (2): Trypanosomes
- R 1 ′ and R 2 ′ each independently represent a hydrogen atom, a C alkyl group, or a C
- R 6 'and R 7 ' are each independently a hydrogen atom, a halogen atom, a hydroxyl group, an oxygen atom, a C alkyl group, C Alkoxy group or C
- X represents a sulfur atom or an oxygen atom.
- K ′ represents 1 or 2 necessary to make the charge of the whole molecule zero. ).
- the present invention provides [3]-The compound described in [1] above, wherein the compound represented by the general formula (1) is a compound represented by the following general formula (3): Antitrypanosomes
- R 6 ′ and R 7 ′ each independently represent a hydrogen atom, a halogen atom, a hydroxyl group, an oxygen atom, a C alkyl group, a C alkoxy group, or a C aryl group, and are bonded to each other.
- A represents a 5-membered or 6-membered heterocyclic ring, or a condensed ring in which 1 or 2 or more 3- to 8-membered rings are condensed, and k ′ represents zero charge of the whole molecule.
- Indicates 1 or 2 required for And [4] Q is a halogen ion, a sulfonate ion, or a carboxylate ion, and relates to the antitrypanosome agent according to any one of [1] to [3] above.
- the antitrypanosome agent of the present invention is not particularly limited as long as it is a pharmaceutical composition containing a compound represented by the following general formula (1) as an active ingredient. These compounds may be contained alone or in combination of two or more, and are usually contained together with a pharmaceutically acceptable carrier or diluent.
- Examples of the halogen atom represented by R 1 and R 2 in the general formula (1) include chlorine, bromine, fluorine, iodine and the like.
- the C alkyl group represented by R 1 and R 2 in the general formula (1) may be branched even if it is linear.
- alkyl groups that may be substituted include alkyl groups having 1 to 5 carbon atoms, alkenyl groups having 2 to 5 carbon atoms, alkyl groups having 2 to 5 carbon atoms, and carbon.
- alkyl group represented by R1 and R2 include a methyl group, an ethyl group, a hydroxyethyl group, a 2-propyl group, a benzyl group, a propyl group, and a butyl group.
- the C alkoxy group represented by R 1 and R 2 in the general formula (1) may be a linear group.
- R 1 and R 2 examples include methoxy group, ethoxy group, hydroxyethoxy group, 2-propenyloxy group, benzyloxy group, propoxy group, butoxy group and the like.
- Examples of the group include the same groups as those in the alkyl group.
- Specific examples of the C aryl group represented by R 1 and R 2 include a phenol group, a tolyl group, and a p-chlorophenyl group.
- substituents examples include the same as those in the alkyl group.
- C5-8 aryloxy group represented by R 1 and R 2 include a phenoxy group, a triloxy group, and a p-chlorophenoxy group.
- the C alkoxycarbonyl group represented by R 1 and R 2 in the general formula (1) is not substituted.
- Examples of the substituent are the same as those in the above alkyl group.
- Specific examples of the C2-6 alkoxycarbonyl group represented by R1 and R2 include a methoxycarbon group and an ethoxycarbonyl group.
- substituents examples include those similar to those in the above alkyl group.
- Specific examples of the C 1 alkylaminocarboyl group represented by R 1 and R 2 include aminomethyl.
- R 1 and R 2 may be bonded to each other.
- one or two or more 3- to 8-membered rings can be formed.
- a benzene ring, a naphthalene ring, or the like can be formed.
- R 3 , R 4 and R 5 are each independently a C alkyl group or C alkyl.
- R 6 and R 7 are each independently a hydrogen atom, a halogen atom, a hydroxyl group, an oxygen atom, a C alkyl group, a C alkoxy group, a C aryl group, a C aryloxy group.
- R 1 and R 2 may be bonded to each other, for example, 1 or 2 or more 3- to 8-membered rings can be formed, specifically, a benzene ring, a naphthalene ring or the like is formed. be able to.
- Y and Z each independently represent an atomic group necessary for forming a 5-membered or 6-membered heterocyclic ring.
- the 5-membered or 6-membered heterocycle formed by Y and Z in the general formula (1) is included in a heterocycle that can be a saturated ring or an unsaturated ring.
- the hetero atom include a nitrogen atom, an oxygen atom, a sulfur atom, a selenium atom, a tellurium atom, a key atom, and a phosphorus atom.
- Y and Z may have 1 or 2 or more substituents, and the substituents are the same as those of the alkyl group represented by R 1 and R 2 in the general formula (1). Can be mentioned.
- 5-membered or 6-membered heterocyclic ring formed by Y and Z include thiazole-based rings (for example, thiazole, 4-methylthiazole, 4-phenolthiazole, 4, 5- Diphenylthiazole, 4,5-dimethylthiazole, etc.), benzothiazole ring (eg, benzothiazole, 5-methylbenzothiazole, 5-phenol benzothiazole, 5-methoxybenzothiazole, 4 fluorobenzothiazole 5,6-Dioxymethylene benzothiazole, 5-Nitrobenzothiazole, 5-Trifluoromethylbenzothiazole, 5-Methoxycarbonylbenzothiazole, 6-Hydroxybenzothiazole, 5-Cyanobenzothiazole, 5- Such as ⁇ -naphthothiazole, j8-naphthothiazole, ⁇ -naphthothiazole, 5-methoxy-13 naphthothi
- Q represents a physiologically acceptable ion.
- a strong physiologically acceptable anion is nontoxic when a compound represented by the general formula (1) is administered to a recipient, and the compound represented by the general formula (1) is an aqueous system.
- Means ions dissolved in Physiologically acceptable ions represented by Q include, for example, halogen ions such as chloride ion, bromide ion and iodine ion; methanesulfonate ion, trifluoromethanolonerephonic acid, ⁇ Sulfate ions such as aliphatic and aromatic sulfonate ions such as 2-hydroxyethane sulfonate ions; sulfamate ions such as cyclohexane sulfamate ions; Sulfate ions such as sulfate ion and ethyl sulfate ion; Hydrogen sulfate ion; Borate ion; Jetyl phosphate
- m and n each represent 0 or 1
- k represents an integer of 0 to 2 required to make the charge of the whole molecule zero.
- the compound represented by the general formula (1) is preferably a compound represented by the following general formula (2) or the following general formula (3).
- R 1 ′ and R 2 ′ are each independently a hydrogen atom, a C alkyl group,
- R 1 ′ and R 2 ′ may be bonded to each other, for example, 1 or 2 or more 3- to 8-membered rings can be formed. Specifically, a benzene ring, a naphthalene ring or the like can be formed. Can be formed.
- R 6 ′ and R 7 ′ each independently represent a hydrogen atom, a halogen atom, a hydroxyl group, an oxygen atom, a C alkyl group, a C alkoxy group, or a C aryl group. Represent it
- R 6 ′ and R 7 may be bonded to each other, for example, can form one or two or more 3- to 8-membered rings, and specifically include a benzene ring, a naphthalene ring, and the like. Can be formed.
- X represents a sulfur atom or an oxygen atom.
- k ′ represents 1 or 2 necessary to make the charge of the whole molecule zero.
- R 6 ′ and R 7 ′ each independently represent a hydrogen atom, a halogen atom, a hydroxyl group, an oxygen atom, a C alkyl group, a C alkoxy group, or a C aryl group. Represent it
- R 6 and R 7 in the general formula (1) are synonymous with those represented by R 6 and R 7 in the general formula (1).
- R 6 ′ and R 7 ′ may be bonded to each other.
- one or two or more 3- to 8-membered rings can be formed.
- a benzene ring, a naphthalene ring, etc. can be formed.
- A represents a 5-membered or 6-membered heterocyclic ring, or a condensed ring obtained by condensing one or two or more 3- to 8-membered rings.
- a 5-membered or 6-membered heterocyclic ring has the same meaning as that represented by Y and Z in formula (1).
- the 3- to 8-membered ring in the condensed ring represented by A in which 1 or 2 or more 3- to 8-membered rings are condensed to the 5-membered or 6-membered ring may be a saturated ring or an unsaturated ring.
- cyclopropane ring, cyclopropene ring, cyclobutane ring, cyclobutene ring, cyclopentane ring, cyclopentene ring, cyclohexane ring, cyclohexene ring, cycloheptane ring, cycloheptene ring, cyclooctane ring examples thereof include a cyclootaten ring, a benzene ring, a naphthalene ring, an anthracene ring, a phenanthrene ring, a thiophene ring, and a pyridine ring.
- a 5-membered ring or a 6-membered ring is particularly preferable.
- substituent which A may have 1 or 2 or more substituents include those similar to the substituents of the alkyl group represented by R1 and R2 in the general formula (1). It is done.
- k ' represents 1 or 2 necessary to make the charge of the whole molecule zero.
- the compounds represented by the general formulas (1) to (3) of the present invention are disclosed in JP-A-5-117148, JP-A-2000-191531, JP-A-2003-0334640, JP-A-2003-2003. — 034641, JP2003-034642, Japanese Patent Application 2003-128454, Takasu, K, et al., Journal of Medicinal Chemistry, 2002, 45 ⁇ , pages 995-998, Takasu, K, According to the method disclosed in et al., Journal of Combinatorial Chemistry, 2003, 5 pp. 211-214, it can be easily produced from known starting materials.
- Typical examples of the compounds represented by the general formulas (1) to (3) of the present invention include the following compounds, but are not limited to these compounds.
- the anti-trypanosomes of the present invention can be used effectively for the prevention or treatment of trypanosomes including African trypanosomes and American trypanosomes.
- the antitrypanosome agent of the present invention can contain an antitrypanosomer agent that has been used in the past as needed.
- Preferable examples of such antitrypanosomes that have been used conventionally include pentamidine, meralsoprole, benznidazole and the like.
- a pharmaceutical carrier or diluent that can be used with the compounds represented by the general formulas (1) to (3) of the present invention
- a conventionally used pharmaceutical carrier or diluent is used.
- a pharmaceutically effective amount and a method of administration of the compounds represented by the general formulas (1) to (3) of the present invention depends on the type of parasitic protozoa that causes the infection, the site of the protozoan parasite, the severity of the condition, the treatment policy, the patient's age, weight, sex, general health condition, and the patient's (genetic) Depending on racial background.
- the dose of the present invention is 1 to 2000 mg, more generally 50 to 500 mg Z day Z body weight 70 kg.
- a suitable administration method is, for example, a form dissolved in 5% glucose aqueous solution.
- injection may be intravenously, intraperitoneally, subcutaneously, oral force may be taken, or applied to the skin.
- Trypanosoma brucei rhodensiense (STIB900 strain) protozoan blood flow respiratory type tripomastigote body was used.
- the medium used in the experiment was sterilized by filtration in MEM medium, 25 mM N-2-hydroxyethylpiperazine 2 ethanethrophonic acid (HEPES), lgZL glucose, 1% MEM non-essential amino acid, 0.2 mM 2-mercapto.
- Ethanol, 2 mM sodium pyruvate flame, 0. ImM hypoxanthine and 15% heat-treated horse serum were used.
- Protozoan culture is performed in air at a CO concentration of 5%
- the compound of the present invention and the positive target drug (Meralsoprol) used in the test were dissolved in dimethyl sulfoxide (DMSO) to prepare a test solution having a predetermined concentration.
- DMSO dimethyl sulfoxide
- the test solution was taken in duplicate. After culturing the culture plate in an incubator for 72 hours, the growth inhibitory activity was assayed. The test was performed as follows.
- Rat-derived L6 cells (rat skeletal myoblast cells) were used.
- the medium is RPMI 1640 medium supplemented with 1% L-glutamine (200mM) and 10% fetal calf serum.
- the cells were cultured at a concentration of 5% and 37 ° C.
- the compound of the present invention or the target drug used for the test was dissolved in DMSO to obtain a test solution having a predetermined concentration.
- Preculture was performed, and the medium containing cells in the logarithmic growth phase was taken into a well of a 96-well culture plate, and then a test solution containing a predetermined concentration of drug or DMS O containing no drug was prepared.
- the test solution was duplicated. After culturing the culture plate in an incubator for 72 hours, the growth inhibitory activity was assayed.
- the test was performed as follows.
- Table 1 shows the IC values and selective toxicity coefficients of the samples for the compounds of the present invention and the positive target drug for all African Trypanosoma protozoa and rat L6 cells.
- amastigotes and tripomastigotes infected with Trypanosoma cruzi (Tulahuen C2C4 strain) protozoan rat L6 cells were used.
- the medium used in the experiment was added to RPMI1640 medium containing L6 cells so that L-glutamine (200 mM) was 1% and fetal bovine serum was 10%, and the CO concentration was 5%.
- the compound of the present invention and the positive target drug (benznidazole) used in the test were dissolved in DMSO to obtain a test solution having a predetermined concentration.
- a medium containing 5 ⁇ 10 3 protozoa was added to the wells of a 96-well culture plate and pre-cultured for 48 hours. After changing the medium, DMS 0 was added without a test solution or drug containing a predetermined concentration of drug.
- the test solution was duplicated. After culturing the culture plate in an incubator for 96 hours, the growth inhibitory activity was assayed. The test was performed as follows.
- Each well was covered with 50 ⁇ L of CPRGZNonidet and allowed to stand for another 2-6 hours.
- the culture plate was attached to an absorption microplate reader, the absorbance at 540 nm was measured, and the trypanosomes protozoa infection rate of the test solution addition group and the control was calculated.
- the growth inhibition rate was calculated from the protozoa infection rate obtained above by the following formula, and the 50% growth inhibition concentration (IC) was obtained.
- the selective toxicity coefficient used as an indicator of selective toxicity to American 'trypanosomyma parasites was calculated by the following formula, and the efficacy was evaluated.
- the compound of the present invention exhibited a growth inhibitory effect equivalent to or higher than that of the existing drug benznidazole. In addition, it did not show strong toxicity to normal cells.
- the compound of the present invention showed growth inhibition of African Trypanosoma protozoa and American Trypanosoma protozoa even at low doses, and high doses were administered. Also revealed that mammalian cells were not damaged compared to protozoa. In other words, these facts revealed that the compounds of the present invention are suitable for preventive or therapeutic agents for Turin V sarcosis including African 'trypanosomes and American' trybanosomes.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT05788281T ATE531714T1 (de) | 2004-10-04 | 2005-09-29 | Anti-trypanosomiasis-mittel |
CN2005800334552A CN101107246B (zh) | 2004-10-04 | 2005-09-29 | 抗锥虫病剂 |
US11/576,426 US7795285B2 (en) | 2004-10-04 | 2005-09-29 | Anti-trypanosomiasis agent |
EP05788281A EP1818334B1 (en) | 2004-10-04 | 2005-09-29 | Anti-trypanosomiasis agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-291996 | 2004-10-04 | ||
JP2004291996A JP4553354B2 (ja) | 2004-10-04 | 2004-10-04 | 抗トリパノソーマ剤 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006038513A1 true WO2006038513A1 (ja) | 2006-04-13 |
Family
ID=36142590
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/017927 WO2006038513A1 (ja) | 2004-10-04 | 2005-09-29 | 抗トリパノソーマ剤 |
Country Status (6)
Country | Link |
---|---|
US (1) | US7795285B2 (ja) |
EP (1) | EP1818334B1 (ja) |
JP (1) | JP4553354B2 (ja) |
CN (1) | CN101107246B (ja) |
AT (1) | ATE531714T1 (ja) |
WO (1) | WO2006038513A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090076067A1 (en) * | 2005-06-24 | 2009-03-19 | Japan Science And Technology Agency | Pharmaceutical composition comprising azarhodacyanine compound as active ingredient |
FR2952382B1 (fr) * | 2009-11-10 | 2011-11-25 | Univ Victor Segalen Bordeaux 2 | Vaccins et diagnostics contre les trypanosomoses animales africaines |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000191531A (ja) * | 1998-12-28 | 2000-07-11 | Fuji Photo Film Co Ltd | 抗マラリア剤 |
JP2002524524A (ja) * | 1998-09-14 | 2002-08-06 | スターファーマ・リミテッド | 陰イオン性または陽イオン性デンドリマー抗微生物または抗寄生虫組成物 |
JP2003034642A (ja) * | 2001-07-19 | 2003-02-07 | Japan Science & Technology Corp | ロダシアニン色素化合物を含有する抗マラリア剤 |
JP2003034641A (ja) * | 2001-07-19 | 2003-02-07 | Japan Science & Technology Corp | ロダシアニン系色素化合物を含有する抗マラリア剤 |
JP2003034640A (ja) * | 2001-07-19 | 2003-02-07 | Japan Science & Technology Corp | 四環性複素化合物を含有する抗マラリア剤 |
JP2004509083A (ja) * | 2000-09-01 | 2004-03-25 | スミスクライン・ビーチャム・コーポレイション | 治療方法 |
JP2004331545A (ja) * | 2003-05-06 | 2004-11-25 | Japan Science & Technology Agency | 抗リーシュマニア剤 |
-
2004
- 2004-10-04 JP JP2004291996A patent/JP4553354B2/ja active Active
-
2005
- 2005-09-29 EP EP05788281A patent/EP1818334B1/en active Active
- 2005-09-29 US US11/576,426 patent/US7795285B2/en active Active
- 2005-09-29 AT AT05788281T patent/ATE531714T1/de active
- 2005-09-29 WO PCT/JP2005/017927 patent/WO2006038513A1/ja active Application Filing
- 2005-09-29 CN CN2005800334552A patent/CN101107246B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002524524A (ja) * | 1998-09-14 | 2002-08-06 | スターファーマ・リミテッド | 陰イオン性または陽イオン性デンドリマー抗微生物または抗寄生虫組成物 |
JP2000191531A (ja) * | 1998-12-28 | 2000-07-11 | Fuji Photo Film Co Ltd | 抗マラリア剤 |
JP2004509083A (ja) * | 2000-09-01 | 2004-03-25 | スミスクライン・ビーチャム・コーポレイション | 治療方法 |
JP2003034642A (ja) * | 2001-07-19 | 2003-02-07 | Japan Science & Technology Corp | ロダシアニン色素化合物を含有する抗マラリア剤 |
JP2003034641A (ja) * | 2001-07-19 | 2003-02-07 | Japan Science & Technology Corp | ロダシアニン系色素化合物を含有する抗マラリア剤 |
JP2003034640A (ja) * | 2001-07-19 | 2003-02-07 | Japan Science & Technology Corp | 四環性複素化合物を含有する抗マラリア剤 |
JP2004331545A (ja) * | 2003-05-06 | 2004-11-25 | Japan Science & Technology Agency | 抗リーシュマニア剤 |
Non-Patent Citations (4)
Title |
---|
HOWARTH J ET AL: "1,4-Dihydroxy-2,3-dioxatricyclo[8.4.0.0(4,9)]tetradecane and derivatives with in vitro activity against Plasmodium falciparum, Trypanasoma b brucei, Trypanasoma cruzi, and Leishmaniasis infantum.", BIOORG & MED CHEM LETT., vol. 13, 2003, pages 2013 - 2015, XP002993397 * |
JONES MS ET AL: "Analogues of thiolactomycin as potential anti-malarial and anti-trypanosomal agents.", BIOORG & MED CHEM., vol. 12, 2004, pages 683 - 692, XP002993398 * |
TAKASU K ET AL: "ANTILEISHMANIAL ACTIVITIES OF RHODACYANINE DYES.", HETEROCYCLES., vol. 64, 2004, pages 215 - 221, XP002993399 * |
TAKASU K ET AL: "Rhodacyanine dyes as antimalarials. 1. Preliminary evaluation of their activity and toxicity.", J MED CHEM., vol. 45, 2002, pages 995 - 998, XP002957612 * |
Also Published As
Publication number | Publication date |
---|---|
EP1818334A4 (en) | 2010-02-24 |
JP4553354B2 (ja) | 2010-09-29 |
EP1818334A1 (en) | 2007-08-15 |
EP1818334B1 (en) | 2011-11-02 |
ATE531714T1 (de) | 2011-11-15 |
US20080045574A1 (en) | 2008-02-21 |
US7795285B2 (en) | 2010-09-14 |
CN101107246B (zh) | 2011-04-20 |
JP2006104115A (ja) | 2006-04-20 |
CN101107246A (zh) | 2008-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69916881T2 (de) | Antihypertriglyceridemische, antihyperglykemische, antiangiogene und wundheilende substituierte indolalkansäure | |
CA2332271C (en) | Selective cyclooxygenase-2 anti-inflammatory eye drops | |
US20140107123A1 (en) | Therapeutic Methods For Type I Diabetes | |
AU2019351122A1 (en) | Inhibitors of VAP-1 | |
TWI286476B (en) | Combination of cytochrome P450 dependent protease inhibitors | |
CN105163584A (zh) | 用于治疗癌症的化合物 | |
EA020526B1 (ru) | Применение n-(4-((3-(2-амино-4-пиримидинил)-2-пиридинил)окси)фенил)-4-(4-метил-2-тиенил)-1-фталазинамина для лечения резистентного к антимитотическому агенту рака | |
MA46268B1 (fr) | Dérivés de 5-[2-(pyridin-2-ylamino)-1 ,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-one et leur utilisation en tant qu'inhibiteurs doubles de phosphatidylinositol 3-kinase delta & gamma | |
Bhagdev et al. | Benzothiazole: As an antidiabetic agent | |
JP5942131B2 (ja) | 炎症及び血管増殖に関連する眼疾患の治療法 | |
JP7033317B2 (ja) | 白内障の予防剤、治療剤、およびこれらを製造するためのhat阻害剤の使用 | |
WO2006038513A1 (ja) | 抗トリパノソーマ剤 | |
US20110118317A1 (en) | Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism | |
US8193224B2 (en) | Medicinal composition for prevention or treatment of parasitic protozoan infection | |
JP4090133B2 (ja) | 抗マラリア剤 | |
EP3498277B1 (en) | Pharmaceutical composition for stroke treatment based on ampk inhibition | |
KR920019785A (ko) | 벤조티아졸 유도체 | |
JPWO2006137258A1 (ja) | アザロダシアニン化合物を有効成分として含有する医薬組成物 | |
WO2021193835A1 (ja) | 抗炎症型免疫強化剤 | |
WO2009121015A2 (en) | Methods of treating epithelial injury | |
JPH0733657A (ja) | 癌の光化学療法用又は診断用医薬組成物 | |
JP2002265355A (ja) | 糖尿病由来虚血性心疾患の治療及び/または予防剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 200580033455.2 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005788281 Country of ref document: EP Ref document number: 2547/DELNP/2007 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11576426 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005788281 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11576426 Country of ref document: US |